title: Inhibitors of soluble epoxide hydrolase attenuate vascular smooth muscle cell proliferation.
abstract: Atherosclerosis, in its myriad incarnations the foremost killer disease in the industrialized world, is characterized by aberrant proliferation of vascular smooth muscle (VSM) cells in part as a result of the recruitment of inflammatory cells to the blood vessel wall. The epoxyeicosatrienoic acids are synthesized from arachidonic acid in a reaction catalyzed by the cytochrome P450 system and are vasoactive substances. Metabolism of these compounds by epoxide hydrolases results in the formation of compounds that affect the vasculature in a pleiotropic manner. As an outgrowth of our observations that urea inhibitors of the soluble epoxide hydrolase (sEH) reduce blood pressure in spontaneously hypertensive rats as well as the findings of other investigators that these compounds possess antiinflammatory actions, we have examined the effect of sEH inhibitors on VSM cell proliferation. We now show that the sEH inhibitor 1-cyclohexyl-3-dodecyl urea (CDU) inhibits human VSM cell proliferation in a dose-dependent manner and is associated with a decrease in the level of cyclin D1. In addition, cis-epoxyeicosatrienoic acid mimics the growth-suppressive activity of CDU; there is no evidence of cellular toxicity or apoptosis in CDU-treated cells when incubated with 20 microM CDU for up to 48 h. These results, in light of the antiinflammatory and antihypertensive properties of these compounds that have been demonstrated already, suggest that the urea class of sEH inhibitors may be useful for therapy for diseases such as hypertension and atherosclerosis characterized by exuberant VSM cell proliferation and vascular inflammation.
authors.affiliation: Division of Nephrology, Department of Internal Medicine, University of California, Davis, CA 95616, USA.
authors.forename: Benjamin B
authors.initials: BB
authors.lastname: Davis
authors.forename: David A
authors.initials: DA
authors.lastname: Thompson
authors.forename: Laura L
authors.initials: LL
authors.lastname: Howard
authors.forename: Christophe
authors.initials: C
authors.lastname: Morisseau
authors.forename: Bruce D
authors.initials: BD
authors.lastname: Hammock
authors.forename: Robert H
authors.initials: RH
authors.lastname: Weiss
mesh_terms: D015153:Blotting, Western; D002455:Cell Division / Q000187:drug effects; D002460:Cell Line; D002467:Cell Nucleus / Q000378:metabolism; D002478:Cells, Cultured; D016895:Culture Media, Serum-Free / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D004791:Enzyme Inhibitors / Q000494:pharmacology; D004851:Epoxide Hydrolases / Q000037:antagonists & inhibitors*; D016193:G1 Phase; D006801:Humans; D020935:MAP Kinase Signaling System; D009130:Muscle, Smooth / Q000166:cytology; D009131:Muscle, Smooth, Vascular / Q000166:cytology*; D011994:Recombinant Proteins / Q000378:metabolism; D016196:S Phase; D013936:Thymidine / Q000494:pharmacology; D013997:Time Factors; D014508:Urea / Q000031:analogs & derivatives / Q000494:pharmacology
chemical_list: C450146:1-cyclohexyl-3-dodecylurea; D016895:Culture Media, Serum-Free; D004791:Enzyme Inhibitors; D011994:Recombinant Proteins; D014508:Urea; D004851:Epoxide Hydrolases; D013936:Thymidine